ANIK Q4 2017 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q4 2017 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$29M+2.3% YoY

Gross Profit

$21M70.3% margin

Operating Income

$10M33.1% margin

Net Income

$8M27.4% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

+8.1%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$283M

Total Liabilities

$19M

Stockholders' Equity

$263M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$29M	+2.3%
Gross Profit	$21M	$21M	-2.4%
Operating Income	$10M	$13M	-23.6%
Net Income	$8M	$8M	-0.2%

Revenue Segments

Orthobiologics

$25M87%

Dermal

$2M5%

Other

$1M5%

Surgical

$867,0003%

Geographic Segments

UNITED STATES

$24M90%

Europe

$3M10%